Avadel Pharmaceuticals plc  - AVDL NASDAQ - Trading Alert


ALERT - AVDL Bounces Off Base and Moves Higher - We expect these shares to spike once again testing $11.60 on volume and then advancing to the $18.00 level, doubling once again .

This company is rapidly taking market share away from its top competitor .This stock is covered by 6 analysts, 4 analysts issuing a STRONG BUY .

Taking Market Share Away From Competitor - AVDL Fact Sheet - Zachs Research

 

Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results

DUBLIN, Ireland, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its fourth quarter and full year 2016 financial results on Tuesday, March 7, 2017, before the market open. A conference call to discuss these results has been scheduled for Tuesday, March 7, 2017 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (international). The conference ID number is 69283135. A live audio webcast and accompanying slides can be accessed by visiting the “News & Events” page of the Company’s Investors website at www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc: 
Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel currently markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

DUBLIN, Ireland, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that management will present at two upcoming investor conferences:

  • LEERINK Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:00 a.m. Eastern Time in New York City
     
  • RBC Capital Markets 2017 Global Healthcare Conference on Thursday, February 23, 2017 at 9:30 a.m. Eastern Time in New York City

A live audio webcast of both presentations can be accessed at the “News & Events” section of the Company’s website, www.avadel.com. A replay of these webcasts will be available for 90 days following the event.

About Avadel Pharmaceuticals plc: 
Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel currently markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Forward and Cautionary Statement - Disclaimer

About TopStockReporter.com : 

TopStockReporter.com
  , a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. 

A complete disclaimer can be viewed 
HERE

 

 




















X










 

 

 

 

 

 

 

 

 

 

 

X